Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry (Not Accredited) Programme

All Participant Report

Distribution - 252601 | Sample - 033 | Participant ID -

Date Issued - 02 September 2025 | Closing Date - 22 September 2025 | Machine Used - FACSCanto II

Trial Comments

This exercise was issued to 83 participants of which 73 (88.0%) returned results within the trial window. Of the non-returning centres, there were three extension requests but no pre-notified non-returns at the time of report production.

For samples 33 and 34, a single participant (1.4%) reported a result of MRD negative. The participant reported quantitative results of 0.00012% and 0.00005%, respectively, which was below their stated lower limit of detection. For sample 34, two participants (2.7%) reported their results as MRD below quantifiable limits, with quantitative levels of 0.04% and 0.0351% respectively. There was no methodological correlation between these laboratories. Please note, sufficient cells were provided in this round to fully quantify and report the MRD levels present . Repeat samples are standardly available for all trial issues. The following publication is useful when calculating limits of detection and quantification: Arroz M, et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016 Jan;90(1):31-9.

Sample Comments

This sample contained stabilised whole blood and stabilised plasma cell material.

Results and Performance

Percentage MRD Population	Your Results (%)	Robust Mean (%)	Robust SD (%)	Uncertainty of the Assigned Value (Robust Mean)
	0.0900	0.0520	0.0306	± 0.0050

Percentage MRD Population	z Score*	Performance Status for this Sample	Performance Status Classification Over 12 Sample Period		
			Satisfactory	Action	Critical
	1.24	Satisfactory	12	0	0

***z Score Limits Definitions**

Please note the scale below is applicable to the tables above and to the z score histograms and Shewhart control charts that follow. It is not applicable to the Cusum control charts.



	Your Result	Consensus*
Interpretation	MRD Present	MRD Present
Total Denominator Events	106000	985,504
Total Number of MRD Events	95	383
Percentage MRD	0.0900	0.0520
Total Number of Events Acquired	112,000	1,271,878

* consensus data shown are median values for events acquired and robust mean for percentage MRD

	Your Technique	Returns (n)
Lysis Method	Stain Lyse Wash	24
Doublets Excluded	Yes	57
Number of MRD Events to Define a Population	20	37
Denominator Used	All BM Nucleated Cells	37
Stated Limit of Detection of Assay	0.0200%	
Stated Limit of Quantification of Assay	0.0500%	
Calculated Limit of Detection Based on Events Collected	0.0189%	

Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry (Not Accredited) Programme

Histograms of Participant z Scores

Percentage MRD Population -

Please note ▼ denotes your result



Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry (Not Accredited) Programme

Shewhart Control Charts

(Please note each data point represents a single sample)

Values (Percentage MRD Population)



Cusum Control Charts

(Please note each data point represents the sum of the z scores of the current sample and the two previous samples)

Values (Percentage MRD Population)



Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry (Not Accredited) Programme

(Please note robust stats are only displayed for groups of 20 or more)

Flow Cytometer Specific Statistics

Method	Percentage MRD					
	Returns	Robust Mean	Robust SD	Median	Lower Quartile	Upper Quartile
CytoFlex	1	-	-	-	-	-
DxFLEX	10	-	-	-	-	-
FACScan	1	-	-	-	-	-
FACSCanto II	13	-	-	-	-	-
FACSLyric	33	0.0523	0.0261	0.0550	0.0340	0.0700
LSR	1	-	-	-	-	-
LSRFortessa	1	-	-	-	-	-
Navios	8	-	-	-	-	-
Northern Lights	1	-	-	-	-	-

(Please note robust stats are only displayed for groups of 20 or more)

MRD Group Specific Statistics

Method	Percentage MRD					
	Returns	Robust Mean	Robust SD	Median	Lower Quartile	Upper Quartile
EuroFlow	9	-	-	-	-	-
NOPHO	2	-	-	-	-	-
Not Affiliated	49	0.0526	0.0336	0.0550	0.0291	0.0760
Other	9	-	-	-	-	-

(Please note robust stats are only displayed for groups of 20 or more)

Technique Specific Statistics

Lysis Technique

Method	Percentage MRD					
	Returns	Robust Mean	Robust SD	Median	Lower Quartile	Upper Quartile
Lyse Stain No Wash	2	-	-	-	-	-
Lyse Stain Wash	40	0.0464	0.0234	0.0450	0.0309	0.0603
Stain Lyse No Wash	2	-	-	-	-	-
Stain Lyse Wash	24	0.0665	0.0370	0.0700	0.0415	0.0900

(Please note robust stats are only displayed for groups of 20 or more)

Doublet Exclusion

Method	Percentage MRD					
	Returns	Robust Mean	Robust SD	Median	Lower Quartile	Upper Quartile
No	11	-	-	-	-	-
Yes	57	0.0541	0.0303	0.0570	0.0320	0.0720

(Please note robust stats are only displayed for groups of 20 or more)

Denominator

Method	Percentage MRD					
	Returns	Robust Mean	Robust SD	Median	Lower Quartile	Upper Quartile
All BM Nucleated Cells	37	0.0491	0.0322	0.0480	0.0300	0.0700
Other	2	-	-	-	-	-
Total Leucocytes	29	0.0562	0.0301	0.0573	0.0330	0.0736

Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry (Not Accredited) Programme

Reported Staining Intensity (numbers differ from antibody usage table as not all centres submitted full results)

Antigen	Absent		Weak		Strong		Total
	n	%	n	%	n	%	
CD38	0	0.0	10	15.6	54	84.4	64
CD19	46	74.2	8	12.9	8	12.9	62
CD138	0	0.0	14	23.3	46	76.7	60
CD45	6	10.3	38	65.5	14	24.1	58
CD56	20	34.5	19	32.8	19	32.8	58
CD27	10	20.0	21	42.0	19	38.0	50
CD117	3	6.0	12	24.0	35	70.0	50
CD81	2	4.7	22	51.2	19	44.2	43
IgG Kappa	5	13.9	12	33.3	19	52.8	36
IgG Lambda	26	74.3	2	5.7	7	20.0	35
CD20	10	58.8	3	17.7	4	23.5	17
CD200	1	7.7	4	30.8	8	61.5	13
CD28	3	27.3	5	45.5	3	27.3	11
B2M	0	0.0	0	0.0	3	100.0	3
VS38c	0	0.0	0	0.0	2	100.0	2

Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry (Not Accredited) Programme

Table showing the breakdown of participant returns according to antibody manufacturer

N.B. To allow for concise reports only antigens tested by >=50% of participants and with manufacturer group >20 users across all reagents are shown. Please note, numbers in all tables may not equal the number of participants due to not all participants providing all information or to some participants performing multiple combinations of techniques. The 'Total Results' column reflects all results returned, as small user groups are not shown on the table individual row totals may differ from that shown in 'Total Results'.

Antigen	Result	Intensity	Total Results (All Data)	BD Biosciences	Beckman Coulter	Cytognos	BioLegend	Dako	Other	exbio	Sysmex	Pharmingen	BioRad	invitrogen	Not Stated			
CD19	Negative (-)	Absent	46	18	24	3	1											
		Weak	1		1													
		Strong	2	2														
	Positive (+)	Weak	7	2	4				1									
		Strong	6	1	4									1				
CD27	Negative (-)	Absent	10	4	4	1			1									
		Weak	1		1													
	Positive (+)	Weak	20	10	4		5						1					
		Strong	19	5	5	2	7											
CD38	Positive (+)	Weak	10	3	1	4		1			1							
		Strong	54	20	15	13	1		2	2		1						
CD45	Negative (-)	Absent	6	5			1											
	Positive (+)	Weak	38	15	11	3	6	2	1									
		Strong	14	5	7		1				1							
CD56	Negative (-)	Absent	19	4	10	4			1									
		Weak	1		1													
		Strong	1		1													
	Positive (+)	Absent	1	1														
		Weak	18	10	3	5												
		Strong	18	12	1	3	1	1										
CD81	Negative (-)	Absent	2		1	1												
	Positive (+)	Weak	22	11	1	10												
		Strong	19	7	9	1			1			1						
CD117	Negative (-)	Absent	3	2	1													
	Positive (+)	Weak	12	6	3			1	1	1								
		Strong	35	18	12	3	1	1										
CD138	Positive (+)	Weak	14	7	6					1								
		Strong	46	26	13	3	1		1	1					1			
IgG Kappa	Negative (-)	Absent	4	1				3										
	Positive (+)	Absent	1		1													
		Weak	12	5			1	5			1							
		Strong	19	7		2		8	2									
IgG Lambda	Negative (-)	Absent	26	15	1	2	2	4	2									
		Strong	2	1	1													
	Positive (+)	Weak	2	2														
		Strong	5	3				2										

Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry (Not Accredited) Programme

Table showing the breakdown of participant returns according to antibody fluorochrome

N.B. To allow for concise reports only antigens tested by >=50% of participants and with groups >20 users across all reagents are shown. Please note, numbers in all tables may not equal the number of participants due to not all participants providing all information or to some participants performing multiple combinations of techniques. The 'Total Results' column reflects all results returned, as small user groups are not shown on the table individual row totals may differ from that shown in 'Total Results'.

Antigen	Result	Intensity	Total Results (All Data)	APC	FITC	PE	PE-CY7	APC-H7	BV421	PerCP-CY5.5	BV510	Pacific Blue	APC-Alexa 750	APC-C750	ECD	PC5.5	V450	BV605
CD19	Negative (-)	Absent	46				28		2						4	1	1	
		Weak	1				1											
		Strong	2				1											
	Positive (+)	Weak	7					1			1					1		
		Strong	6							1					1	3		
CD27	Negative (-)	Absent	10				1				3		1			1		1
		Weak	1									1						
	Positive (+)	Weak	20			2	1		1	2	5		1				1	2
		Strong	19		2	3	1		1	1	9				1			1
CD38	Positive (+)	Weak	10		7		1	1							1			
		Strong	54	1	31			2	2	1	1	6	1			1	2	2
CD45	Negative (-)	Absent	6							1							1	
	Positive (+)	Weak	38					2		14	2	3					1	
		Strong	14							2								
CD56	Negative (-)	Absent	19	3		4	1						3		1			
		Weak	1										1					
		Strong	1				1											
	Positive (+)	Absent	1						1									
		Weak	18			14			1				3					
		Strong	18			11	1				2					1		
CD81	Negative (-)	Absent	2									1		1				
	Positive (+)	Weak	22	1	2			4		1		1	1	8				2
		Strong	19	1	5			7		1		3	1					
CD117	Negative (-)	Absent	3	1		1												
	Positive (+)	Weak	12	5		3	2						1		1			
		Strong	35	16		3				1			1		3	2		1
CD138	Positive (+)	Weak	14	5	2				2			1				1	1	
		Strong	46	14		4			16	1	2	1				1	2	
IgG Kappa	Negative (-)	Absent	4	2	2													
	Positive (+)	Absent	1		1													
		Weak	12	9	2	1												
		Strong	19	11	6	2												
IgG Lambda	Negative (-)	Absent	26	2	2	7		10						3				
		Strong	2			2												
	Positive (+)	Weak	2					2										
		Strong	5			3		2										

Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry (Not Accredited) Programme

Distribution - 252601 | Sample - 034 | Participant ID -

Date Issued - 02 September 2025 | Closing Date - 22 September 2025 | Machine Used - FACSCanto II

Trial Comments

This exercise was issued to 83 participants of which 73 (88.0%) returned results within the trial window. Of the non-returning centres, there were three extension requests but no pre-notified non-returns at the time of report production.

For samples 33 and 34, a single participant (1.4%) reported a result of MRD negative. The participant reported quantitative results of 0.00012% and 0.00005%, respectively, which was below their stated lower limit of detection. For sample 34, two participants (2.7%) reported their results as MRD below quantifiable limits, with quantitative levels of 0.04% and 0.0351% respectively. There was no methodological correlation between these laboratories. Please note, sufficient cells were provided in this round to fully quantify and report the MRD levels present . Repeat samples are standardly available for all trial issues. The following publication is useful when calculating limits of detection and quantification: Arroz M, et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016 Jan;90(1):31-9.

Sample Comments

This sample contained stabilised whole blood and stabilised plasma cell material.

Results and Performance

Percentage MRD Population	Your Results (%)	Robust Mean (%)	Robust SD (%)	Uncertainty of the Assigned Value (Robust Mean)
	0.0400	0.0376	0.0185	± 0.0030

Percentage MRD Population	z Score*	Performance Status for this Sample	Performance Status Classification Over 12 Sample Period		
			Satisfactory	Action	Critical
	0.13	Satisfactory	12	0	0

***z Score Limits Definitions**

Please note the scale below is applicable to the tables above and to the z score histograms and Shewhart control charts that follow. It is not applicable to the Cusum control charts.



	Your Result	Consensus*
Interpretation	MRD Detected Below Quantifiable Limits	MRD Present
Total Denominator Events	115000	992,653
Total Number of MRD Events	43	342
Percentage MRD	0.0400	0.0376
Total Number of Events Acquired	122,500	1,179,774

* consensus data shown are median values for events acquired and robust mean for percentage MRD

	Your Technique	Returns (n)
Lysis Method	Stain Lyse Wash	24
Doublets Excluded	Yes	58
Number of MRD Events to Define a Population	20	37
Denominator Used	All BM Nucleated Cells	36
Stated Limit of Detection of Assay	0.0200%	
Stated Limit of Quantification of Assay	0.0500%	
Calculated Limit of Detection Based on Events Collected	0.0174%	

Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry (Not Accredited) Programme

Histograms of Participant z Scores

Percentage MRD Population -

Please note ▼ denotes your result



Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry (Not Accredited) Programme

Shewhart Control Charts

(Please note each data point represents a single sample)

Values (Percentage MRD Population)



Cusum Control Charts

(Please note each data point represents the sum of the z scores of the current sample and the two previous samples)

Values (Percentage MRD Population)



Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry (Not Accredited) Programme

(Please note robust stats are only displayed for groups of 20 or more)

Flow Cytometer Specific Statistics	Percentage MRD					
Method	Returns	Robust Mean	Robust SD	Median	Lower Quartile	Upper Quartile
CytoFlex	1	-	-	-	-	-
DxFLEX	10	-	-	-	-	-
FACSCanto	1	-	-	-	-	-
FACSCanto II	13	-	-	-	-	-
FACSLyric	32	0.0383	0.0194	0.0399	0.0246	0.0500
LSR	1	-	-	-	-	-
LSRFortessa	1	-	-	-	-	-
Navios	8	-	-	-	-	-
Northern Lights	1	-	-	-	-	-

(Please note robust stats are only displayed for groups of 20 or more)

MRD Group Specific Statistics	Percentage MRD					
Method	Returns	Robust Mean	Robust SD	Median	Lower Quartile	Upper Quartile
EuroFlow	9	-	-	-	-	-
NOPHO	2	-	-	-	-	-
Not Affiliated	49	0.0379	0.0210	0.0400	0.0221	0.0500
Other	9	-	-	-	-	-

(Please note robust stats are only displayed for groups of 20 or more)

Technique Specific Statistics

Lysis Technique	Percentage MRD					
Method	Returns	Robust Mean	Robust SD	Median	Lower Quartile	Upper Quartile
Lyse Stain No Wash	3	-	-	-	-	-
Lyse Stain Wash	40	0.0348	0.0167	0.0361	0.0238	0.0434
Stain Lyse No Wash	1	-	-	-	-	-
Stain Lyse Wash	24	0.0429	0.0201	0.0440	0.0350	0.0500
Stain No Lyse No wash	1	-	-	-	-	-

(Please note robust stats are only displayed for groups of 20 or more)

Doublet Exclusion	Percentage MRD					
Method	Returns	Robust Mean	Robust SD	Median	Lower Quartile	Upper Quartile
No	11	-	-	-	-	-
Yes	58	0.0377	0.0191	0.0399	0.0241	0.0500

(Please note robust stats are only displayed for groups of 20 or more)

Denominator	Percentage MRD					
Method	Returns	Robust Mean	Robust SD	Median	Lower Quartile	Upper Quartile
All BM Nucleated Cells	36	0.0351	0.0176	0.0380	0.0243	0.0450
Other	2	-	-	-	-	-
Total Leucocytes	30	0.0419	0.0219	0.0399	0.0259	0.0540

Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry (Not Accredited) Programme

Reported Staining Intensity (numbers differ from antibody usage table as not all centres submitted full results)

Antigen	Absent		Weak		Strong		Total
	n	%	n	%	n	%	
CD38	0	0.0	10	15.6	54	84.4	64
CD19	46	74.2	8	12.9	8	12.9	62
CD138	0	0.0	14	23.3	46	76.7	60
CD45	6	10.3	39	67.2	13	22.4	58
CD56	22	37.9	18	31.0	18	31.0	58
CD27	10	20.0	21	42.0	19	38.0	50
CD117	2	4.0	12	24.0	36	72.0	50
CD81	3	7.1	20	47.6	19	45.2	42
IgG Kappa	5	14.3	12	34.3	18	51.4	35
IgG Lambda	26	76.5	2	5.9	6	17.7	34
CD20	10	58.8	3	17.7	4	23.5	17
CD200	1	7.7	4	30.8	8	61.5	13
CD28	3	27.3	4	36.4	4	36.4	11
B2M	0	0.0	0	0.0	3	100.0	3
VS38c	0	0.0	0	0.0	2	100.0	2

Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry (Not Accredited) Programme

Table showing the breakdown of participant returns according to antibody manufacturer

N.B. To allow for concise reports only antigens tested by >=50% of participants and with manufacturer group >20 users across all reagents are shown. Please note, numbers in all tables may not equal the number of participants due to not all participants providing all information or to some participants performing multiple combinations of techniques. The 'Total Results' column reflects all results returned, as small user groups are not shown on the table individual row totals may differ from that shown in 'Total Results'.

Antigen	Result	Intensity	Total Results (All Data)	BD Biosciences	Beckman Coulter	Cytognos	BioLegend	Dako	Other	exbio	Sysmex	Pharmingen	BioRad	invitrogen	Not Stated			
CD19	Negative (-)	Absent	46	18	24	3	1											
		Weak	1		1													
		Strong	2	2														
	Positive (+)	Weak	7	2	4				1									
		Strong	6	1	4									1				
CD27	Negative (-)	Absent	10	4	4	1			1									
		Weak	1		1													
	Positive (+)	Weak	20	10	4		5						1					
		Strong	19	5	5	2	7											
CD38	Positive (+)	Weak	10	4	1	4					1							
		Strong	54	19	15	13	1	1	2	2		1						
CD45	Negative (-)	Absent	6	5			1											
	Positive (+)	Weak	39	15	12	3	6	2	1									
		Strong	13	5	6		1				1							
CD56	Negative (-)	Absent	21	4	11	4	1		1									
		Weak	1		1													
		Strong	1		1													
	Positive (+)	Absent	1	1														
		Weak	17	10	2	5												
		Strong	17	12	1	3		1										
CD81	Negative (-)	Absent	3		1	2												
	Positive (+)	Weak	20	10	1	9												
		Strong	19	7	9	1			1			1						
CD117	Negative (-)	Absent	2	2														
	Positive (+)	Weak	12	6	3			1	1	1								
		Strong	36	18	13	3	1	1										
CD138	Positive (+)	Weak	14	7	6					1								
		Strong	46	26	13	3	1		1	1					1			
IgG Kappa	Negative (-)	Absent	4	1				3										
	Positive (+)	Absent	1		1													
		Weak	12	5			1	5			1							
		Strong	18	7		2		7	2									
IgG Lambda	Negative (-)	Absent	26	15	1	2	2	4	2									
		Strong	2	1	1													
	Positive (+)	Weak	2	2														
		Strong	4	2				2										

Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry (Not Accredited) Programme

Table showing the breakdown of participant returns according to antibody fluorochrome

N.B. To allow for concise reports only antigens tested by >=50% of participants and with groups >20 users across all reagents are shown. Please note, numbers in all tables may not equal the number of participants due to not all participants providing all information or to some participants performing multiple combinations of techniques. The 'Total Results' column reflects all results returned, as small user groups are not shown on the table individual row totals may differ from that shown in 'Total Results'.

Antigen	Result	Intensity	Total Results (All Data)	APC	FITC	PE	PE-CY7	APC-H7	BV421	PerCP-CY5.5	BV510	Pacific Blue	APC-Alexa 750	APC-C750	ECD	PC5.5	V450	BV605
CD19	Negative (-)	Absent	46				28		2						4	1	1	
		Weak	1				1											
		Strong	2				1											
	Positive (+)	Weak	7					1			1					1		
		Strong	6							1					1	3		
CD27	Negative (-)	Absent	10				1				3		1			1		1
		Weak	1									1						
	Positive (+)	Weak	20			2	1		1	2	5		1				1	2
		Strong	19		2	3	1		1	1	9				1			1
CD38	Positive (+)	Weak	10		7		1	1							1			
		Strong	54	1	31			2	2	1	1	7	1				2	2
CD45	Negative (-)	Absent	6							1							1	
	Positive (+)	Weak	39					2		14	2	3					1	
		Strong	13							2								
CD56	Negative (-)	Absent	21	3		4	1						4		1			
		Weak	1										1					
		Strong	1				1											
	Positive (+)	Absent	1						1									
		Weak	17			14			1				2					
		Strong	17			11	1				2					1		
CD81	Negative (-)	Absent	3					1				1		1				
	Positive (+)	Weak	20	1	1			3		1		1	1	8				2
		Strong	19	1	5			7		1		3	1					
CD117	Negative (-)	Absent	2	1		1												
	Positive (+)	Weak	12	5		3	2						1		1			
		Strong	36	16		3				1			1		3	2		1
CD138	Positive (+)	Weak	14	5	2				2			1				1	1	
		Strong	46	14		4			16	1	2	1				1	2	
IgG Kappa	Negative (-)	Absent	4	2	2													
	Positive (+)	Absent	1		1													
		Weak	12	9	2	1												
		Strong	18	10	6	2												
IgG Lambda	Negative (-)	Absent	26	2	2	7		11						3				
		Strong	2			2												
	Positive (+)	Weak	2					2										
		Strong	4			3		1										

Information with respect to compliance with standards BS EN ISO/IEC 17043:2010

4.8.2 a) The proficiency testing provider for this programme is:
UK NEQAS for Leucocyte Immunophenotyping
Pegasus House, 4th Floor Suite
463A Glossop Road
Sheffield, S10 2QD
United Kingdom
Tel: +44 (0) 114 267 3600
e-mail: amanda.newbould@ukneqasli.co.uk

4.8.2 b) The coordinator(s) of UK NEQAS LI programmes: Mr Stuart Scott (acting Director).

4.8.2 c) Person(s) authorising this report: Mr Stuart Scott (acting Director) of UK NEQAS LI.

4.8.2 d) Administration and shipping for this programme is provided by EQA International Limited. No other activities in relation to this EQA exercise were subcontracted.

4.8.2 d) Where externally provided products or services are used in the delivery of EQA, a competent supplier is used, the EQA provider is responsible for this work and participants are informed accordingly.

4.8.2 g) The UK NEQAS LI Privacy Policy can be found at the following link: https://sheffield-ukneqas.ipassportqms.com/document_download/NjRlNTgxYzctMTI4ZS00MTg4LWI2ZDMtZDdkYzJhMTFlZTg3 Participant details, their results and their performance data remain confidential unless we are required by law to share this information. Where required by law or authorised by contractual arrangements to release confidential information, UK NEQAS LI will notify those concerned of the information released, unless prohibited by law. For UK participants, the relevant National Quality Assessment Advisory Panel is informed when a UK participant is identified as having performance issues.

4.8.2 i) All EQA samples are prepared in accordance with strict standard operating procedures by trained personnel proven to ensure homogeneity and stability. Where appropriate/possible EQA samples are tested prior to issue. Where the sample(s) issued is stabilised blood or platelets, pre and post stability testing will have proved sample suitability prior to issue.

4.8.2 l), n), o), r) & s) Please refer to the UK NEQAS LI website at www.ukneqasli.co.uk for detailed information on each programme including the scoring systems applied to assess performance (for BS EN ISO/IEC 17043:2010 accredited programmes only). Where a scoring system refers to the 'consensus result' this means the result reported by the majority of participants for that trial issue. Advice on the interpretation of statistical analyses and the criteria on which performance is measured is also given. Please note that where different methods/procedures are used by different groups of participants these may be displayed within your report, but the same scoring system is applied to all participants irrespective of method/procedure used.

4.8.2 m) We do not assign values against reference materials or calibrants.

4.8.2 q) Details of the programme designs as authorised by The Steering Committee and Specialist Advisory Group can be found on our website at www.ukneqasli.co.uk. The proposed trial issue schedule for each programme is also available.

4.8.2 t) If you would like to discuss the outcomes of this trial issue, please contact UK NEQAS LI using the contact details provided. Alternatively, if you are unhappy with your performance classification for this trial, please find the appeals procedure at www.ukneqasli.co.uk/contact-us/appeals-and-complaints/

4.8.4) The UK NEQAS LI Policy for the Use of Reports by Individuals and Organisations states that all EQA reports are subject to copyright, and, as such, permission must be sought from UK NEQAS LI for the use of any data and/or reports in any media prior to use. See associated policy on the UK NEQAS LI website: http://www.ukneqasli.co.uk/eqa-pt-programmes/new-participant-information/